@article {1779, title = {Mechanism of the Bioactive Sargassum cristaefolium in Inhibiting Inflammatory Mediators in a Nitroglycerin-Induced Migraine Model in Rats}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {April 2022}, pages = {388-396}, type = {Research Article }, chapter = {388}, abstract = {

Background: Migraine headaches are a form of sterile neurogenic inflammation. The sterile inflammatory process of the trigeminal nerve releases the vasoactive neuropeptide CGRP which stimulates the release of inflammatory mediators. In the incidence of migraine there is an increase in TNF-α and IL-10. Sargassum cristaefolium ethanol extract contains flavonoids, alkaloids, triterpenoids, steroids, and tannins, which has analgesic and anti-inflammatory function. Method: Sargassum cristaefolium was extracted using maceration method with 70\% ethanol as solvent. Animal models were divided into 5 groups and given NTG induction 5 times with 1 day intervals, treated for 3 weeks. All data were analyzed using IBM SPSS version 26.0. Results: Sargassum cristaefolium ethanol extract - CGRP levels β: -0.26, p: 0.17; Sargassum cristaefolium ethanol extract - CGRP expression β: -0.04, p: 0.85; Sargassum cristaefolium ethanol extract - TNF-α levels β: -0.63, p: 0.01; Sargassum cristaefolium ethanol extract - TNF-α expression β: -0.40, p: 0.04; Sargassum cristaefolium ethanol extract - IL-10 levels β: 0.77, p: 0.00; Sargassum cristaefolium ethanol extract - IL-10 expression β: 0.45, p: 0.01. Conclusions: A significant path between the administration of Sargassum cristaefolium ethanol extract and a decrease in TNF-α and an increase in IL-10. But the effect of giving Sargassum cristaefolium ethanol extract on CGRP levels did not have a significant relationship.

}, keywords = {Inflammatory mediator, Migraine, Nitroglycerin, Sargassum cristaefolium}, doi = {10.5530/pj.2022.14.50}, author = {Olivia Mahardani Adam and Jusak Nugraha and Muhammad Hamdan and Agus Turchan} } @article {1811, title = {Role of Alkaloid on Platelet Aggregation and Serotonin in Migraine}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {June 2022}, pages = {629-632}, type = {Research Article}, chapter = {629}, abstract = {

Migraine is a sterile neurogenic inflammation of the trigeminal nerve which releases vasoactive neuropeptides and activates platelets to release vasoactive substances such as serotonin (5-HT). Platelet hyperaggregation occurs in the pathogenesis of migraine caused by one of the stimulatory factors 5-HT. Platelet aggregation is increased and 5-HT levels are elevated in the blood and brain in the early stages of migraine. Alkaloid β-carbolin alkaloids can increase monoamines in brain regions through inhibition of monoamine oxidase (MAO) and inhibition of 5-HT reuptake. Alkaloids in the ethanolic extract of SCE function as analgesics and anti-inflammatory which can reduce pain and improve blood circulation. Sargassum cristaefolium extract (SCE) was measured for its bioactive substance content. The extract was administered to an animal model of intraperitoneal nitroglycerin-induced migraine and examined for platelet levels, platelet aggregation and 5-HT. The results of statistical tests showed an increase in platelets (p\<0.05), an increase in platelet aggregation (p\<0.05) and a decrease in 5-HT (p\<0.05). The relationship between alkaloids and platelets; platelets and platelet aggregation; platelet aggregation and 5-HT and 5-HT levels and migraine incidence (p\<0.05). The alkaloids found in SCE can lower platelet count, decrease platelet aggregation and increase 5-HT levels in migraines.

}, keywords = {Alkaloid, Migraine, Platelet, Platelet aggregation, Serotonin.}, doi = {10.5530/pj.2022.14.81}, author = {Olivia Mahardani Adam and Widjiati Widjiati} } @article {1712, title = {In silico Study on the Promising Active Components of Terpenoid and Fucoidon from Sargassum sp. in Inhibiting CGRP and TNF-α}, journal = {Pharmacognosy Journal}, volume = {13}, year = {2021}, month = {December 2021}, pages = {1715-1719}, type = {Research Article}, chapter = {1715}, abstract = {

Introduction: The new discovery of the active substance in Sargassum sp marks the new era for drug industry as it is very effective as the new migraine medication compared to analgesics which have already been popular previously in treating migraine. By using the in silico methods, this study intended to identify the preventive effect of the active substance in Sargassum sp within the stage of pain and inflammation development in migraine. In migraine pathophysiology, the clinical findings would build and verify the role of CGRP and TNF-α. Methods: This research applied a one-shot experimental study and by employing the potential test through PubChem (https://pubchem.ncbi.nlm.nih.gov/), the result of this study proved that tannins, terpenoids and fucoidone were contained in the active substance of Sargassum sp leading to the possession of potential as the drug to treat migraine. Results: Terpenoids and tannin binding affinity value is higher than other substances. Terpenoids and fucoidon had similar amino acid residues with controls. Seaweed metabolites have great potential as inhibitors of CGRP and TNF-α because the binding affinity score is close to control. Conclusion: The active substance in Sargassum sp has an inhibitory effect on the occurrence of CGRP and TNF-α in migraine based on in silico studies.

}, keywords = {CGRP, Fucoidone, in silico, Sargassum sp., Terpenoid, TNF-α.}, doi = {10.5530/pj.2021.13.221}, author = {Olivia Mahardani Adam and Jusak Nugraha and Mohammad Hasan Machfoed and Agus Turchan} }